设计了四个新的带有端基的四噻吩衍生物,它们由二环己基乙基(DCE4T),二环己基丁基(DCB4T),环己基乙基(CE4T)和环己基丁基(CB4T)组成。所有材料在普通有机溶剂中均显示出高溶解度。紫外可见吸收测量表明,具有不对称取代的环己基端基(CE4T和CB4T)的四噻吩衍生物更喜欢H型聚集,而具有对称取代的环己基端基(DCE4T和DCB4T)的四噻吩衍生物更喜欢J型聚集。通过掠入射宽角X射线散射(GIWAXS)测量分析了新的四噻吩衍生物的分子结构相关堆积(H或J)。包含不对称分子CE4T和CB4T的设备的场效应迁移率非常高,高于10−2 cm 2 V -1 s -1,由于H聚集,而结合了对称分子DCE4T和DCB4T的器件的场效应迁移率很差,低于10 −4 cm 2 V -1 s -1,由于J聚合。更重要的是,薄膜中的H聚集在旋涂薄膜中提供了稳定的晶体形态,因此,使用环己基化的四噻吩的薄
设计了四个新的带有端基的四噻吩衍生物,它们由二环己基乙基(DCE4T),二环己基丁基(DCB4T),环己基乙基(CE4T)和环己基丁基(CB4T)组成。所有材料在普通有机溶剂中均显示出高溶解度。紫外可见吸收测量表明,具有不对称取代的环己基端基(CE4T和CB4T)的四噻吩衍生物更喜欢H型聚集,而具有对称取代的环己基端基(DCE4T和DCB4T)的四噻吩衍生物更喜欢J型聚集。通过掠入射宽角X射线散射(GIWAXS)测量分析了新的四噻吩衍生物的分子结构相关堆积(H或J)。包含不对称分子CE4T和CB4T的设备的场效应迁移率非常高,高于10−2 cm 2 V -1 s -1,由于H聚集,而结合了对称分子DCE4T和DCB4T的器件的场效应迁移率很差,低于10 −4 cm 2 V -1 s -1,由于J聚合。更重要的是,薄膜中的H聚集在旋涂薄膜中提供了稳定的晶体形态,因此,使用环己基化的四噻吩的薄
[EN] BIARYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] BIARYL PYRAZOLES UTILISÉS COMME RÉGULATEURS DE NRF2
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2017060854A1
公开(公告)日:2017-04-13
The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.
[EN] BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME<br/>[FR] DÉRIVÉS BICYCLO[3.2.1]OCTYLAMIDE ET LEURS UTILISATIONS
申请人:LUNDBECK & CO AS H
公开号:WO2012088365A1
公开(公告)日:2012-06-28
The present invention provides bicyclo[3.2.1]octyl amide derivatives of formula (I): wherein L, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof; pharmaceutical compositions and methods using the same.
Efficient Solution-Phase Synthesis of 4,5,7-Trisubstituted Pyrrolo[3,2-<i>d</i>]pyrimidines
作者:Weihe Zhang、Jing Liu、Michael A. Stashko、Xiaodong Wang
DOI:10.1021/co300106f
日期:2013.1.14
an efficient and robust route to synthesize 4,5,7-trisubstituted pyrrolo[3,2-d]pyrimidines as potent kinase inhibitors. This solution-phase synthesis features a SNAr substitution reaction, cross-coupling reaction, one-pot reduction/reductive amination and N-alkylation reaction. These reactions occur rapidly with high yields and have broad substrate scopes. A variety of groups can be selectively introduced